Skip to main content

Table 2 Comorbidities, comedication, self-reported events and adherence in patients contacted by phone using a follow-up survey

From: Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth

Patient condition n (%)
Comorbidities 151 (14.22)
 Hypertension 83 (7.82)
 Diabetes 58 (5.46)
 Asthma 8 (0.75)
 HIV 7 (0.66)
 Other disease 22 (2.07)
Concurrent treatments  
 Dipyrone 222 (20.90)
 Paracetamol 75 (7.06)
 Renin–angiotensin–aldosterone system inhibitors 36 (3.39)
 Orphenadrine 28 (2.54)
 Oral antidiabetics 19 (1.79)
 Ibuprofen 18 (1.69)
 H1-antihistamines 8 (0.75)
 Diuretics 8 (0.75)
 Dimenhydrinate 6 (0.56)
Number of symptoms suggestive of hemolytic anaemia  
 No symptoms 217 (20.43)
 1–2 Symptoms 481 (45.29)
 3–4 Symptoms 307 (28.91)
 5–6 Symptoms 57 (5.37)
Type of symptom suggestive of hemolytic anaemia  
 Dark urine 71 (6.69)
 Yellow skin and / or eyes 419 (39.45)
 Fever 190 (17.89)
 Back pain 511 (48.12)
 Dizziness 586 (55.18)
 Shortness of breath 276 (25.99)
Gastrointestinal changes  
 Stomach ache 463 (43.60)
 Nausea or vomiting 603 (56.78)
 Diarrhea 339 (31.92)
Skin disorders  
 Itchy or burning skin 287 (27.02)
 Red patches or patches on the skin 74 (6.97)
Psychiatric disorders  
 Anxious mood 243 (22.88)
 Depression mood 245 (27.07)
 Hallucination, visual 66 (6.21)
 Lack of appetite 753 (70.90)
Neurological disorders  
 Headache 821 (77.31)
 Agitation and tremors without control 111 (10.08)
Changes in heart rate  
 Accelerated heartbeat 345 (32.49)
Ototoxicity  
 Feeling of loss of balance 392 (36.91)
 Ringing in the ear 130 (12.24)
Adherent to treatment 991 (93.31)
  1. CQ: Chloroquine, PQ: primaquine